Article Text

A3.3 Micro-RNA-34a and micro-RNA-155 unbalance is associated to IL-6/IL-6R pathway in CD14 cells and skin compartment of systemic sclerosis patients
  1. S Alivernini1,
  2. SL Bosello1,
  3. B Tolusso1,
  4. R Benvenuto2,
  5. A Mangoni2,
  6. L Bui2,
  7. S Canestri1,
  8. C Di Mario1,
  9. G Ferraccioli1
  1. 1 Division of Rheumatology, Catholic University, Rome, Italy
  2. 2 Division of Surgical Pathology-Catholic University, Rome, Italy


Background and objectives MicroRNAs (miRs) are post-transcriptional regulators implicated in Systemic sclerosis (SSc). MiR-34a and miR-155 are related to endothelial senescence and inflammation. The aim of the study is to investigate the expression of miR-34a and miR-155 in peripheral blood (PB) CD14 cells and in clinically involved and uninvolved skin paired samples in SSc.

Materials and methods Twenty-seven patients with Raynaud phenomenon (RP) were enrolled, divided into 3 groups: long standing SSc (lsSSc) fulfilling the 1987 ACR criteria (n = 10), early SSc (eSSc) reaching 9 points using the Very Early Diagnosis of Systemic Sclerosis criteria (n = 9) and primary RP (n = 8) respectively. Matched healthy controls (HC) (n = 7) were enrolled. Immunostaining for CD68 was performed on paired skin tissues from SSc patients. miR-34a and miR-155 expression was evaluated by qPCR on CD14 cells isolated by CD14 specific microbeads from PB and on clinically involved and uninvolved skin paired samples. Using HumanTargetScan cross-referenced methodology, IL-6 receptor (IL6-R) was selected as target of miR-34a and miR-155 and experimentally confirmed by qPCR. IL-6 and IL-6R plasma levels were determined by ELISA. CD14 cells from PB of HC (n = 4) were cultured in RPMI, stimulated with IL-6 (30ng/ml) or LPS (100ng/ml) and collected after 48 h to assess miR-34a and miR-155 expression by qPCR.

Results MiR-155 is over-expressed either in eSSc (p = 0.0002) and lsSSc (p = 0.04) compared to HC. MiR-34a expression is increased only in lsSSc compared to HC (p = 0.01). Primary RP patients did not differ for miR-155 and miR-34a expression from HC (p = 0.71). CD68 cells are over-represented in clinically involved skin compared to uninvolved skin paired samples (p = 0.02). MiR-34a is over-expressed in clinically involved skin samples compared to uninvolved skin (p = 0.04).

IL-6R expression is significantly lower in lsSSc and eSSc patients compared to primary RP (p = 0.03 and p = 0.03). IL-6 plasma levels were higher in lsSSc (p = 0.01) as well as in eSSc (p = 0.003) compared to HC whereas no significant difference was found in IL-6R plasma levels. MiR-34a expression directly correlates with the skin score value (R = 0.52, p = 0.03) in SSc patients and with IL-6 plasma levels (R = 0.42; p = 0.01). SSc patients with digital ulcers have higher miR-34a expression than SSc patients without ulcers (p = 0.01). Finally, miR-34a and miR-155 are induced in CD14 cells by IL-6 and LPS in vitro stimulation.

Conclusions MiR-34a and miR-155 expression is unbalanced in CD14 cells and paired skin samples of SSc patients linked to the IL-6/IL-6R pathway. MiRNA expression profile could help to differentiate patients with primary and SSc associated RP.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.